SYBLEU Inc
Healthcare · Pharmaceutical Preparations · WY · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|
| Revenue | $11,696 | $11,700 | $4,052 | — |
| Operating income | −$149,180 | −$56,373 | −$88,252 | −$3,859 |
| Net income | −$29,034 | −$27,030 | −$132,307 | −$21,896 |
| Total assets | $330,468 | $76,379 | $199,547 | $8,550 |
| Total liabilities | $681,413 | $326,338 | $204,161 | $11,329 |
| Equity | −$295,117 | −$225,702 | −$4,614 | −$2,779 |
| EPS (diluted) | — | — | — | — |
| Shares out. | 10.6M | 10.4M | 10.4M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −1275.5%
- Net margin
- −248.2%
- Return on equity
- 9.8%
- Return on assets
- −8.8%
- Return on capital (ROCE)
- −150.6%
- Liabilities / assets
- 206.2%
- Debt / equity
- —
- Book value / share
- $-0.03
- Revenue growth (YoY)
- −0.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -12.94distress
- Accruals / assets
- 21.6%high accruals
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 6 warning● 0 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 16, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Changed auditorMay 23, 2024
- Changed auditorMay 8, 2024
- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Unregistered equity sale · Change in control · Director / officer changeApr 18, 2024
- Entered a material agreementJul 7, 2023
- Entered a material agreementJun 26, 2023
- Other material eventJun 20, 2023
- Entered a material agreement · Change in control · Director / officer changeDec 12, 2022
- Prior financials not reliable (restatement)Mar 16, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.